February 8, 2024 11:25 AM ESTUpdated 03:22 PM
Pharma

Wall Street: GLP-1 com­peti­tors’ pain is Eli Lil­ly’s gain

Max Gelman

Senior Editor

Eli Lil­ly’s stock con­tin­ued its wild ride Wednes­day af­ter lack­lus­ter da­ta from Am­gen’s po­ten­tial GLP-1 com­peti­tor fur­ther demon­strat­ed tirzepatide’s ad­van­tage.

On Wednes­day, Lil­ly shares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times